Renaissance Capital logo

NDRM News

Race to the Finnish line: Parkinson's biotech Biotie Therapies files for a $60 million US IPO

Biotie Therapies, a Finnish biotech developing an adjunct therapy to levodopa for Parkinson's disease, filed on Thursday with the SEC to raise up to $60 million in a US initial public offering. The Turku, Finland-based company, which was founded in 1998, plans to list on the NASDAQ under the symbol BITI. Biotie Therapies initially filed confidentially on March 17, 2015. RBC...read more

Parkinson's biotech Civitas Therapeutics officially withdraws IPO; acquired by Acorda for $525 million

Civitas Therapeutics, which is developing an inhaled formulation of an existing drug for Parkinson's Disease, officially withdrew its plans for an initial public offering on Thursday. The company had originally planned to raise $75 million in September. On the day it was expected to price, Civitas announced that it would be acquired by Acorda Therapeutics for $525 million, or a...read more

US IPO Weekly Recap: Virgin America flies high as IPO market reaches 250 with 9 new offerings

VA

9 companies went public this week, raising $2 billion in the IPO market as year-to-date issuance surpassed 250 IPOs, almost 25% more than at this point last year. 3 large PE-backed deals, including two LBOs, each traded up over 10% and represented 79% of proceeds, while the 4 smallest companies by market cap had the lowest returns. Even with the S&P 500 near all-time highs,...read more

Parkinson's biotech NeuroDerm prices IPO below range at $10

NeuroDerm, which is developing a liquid formulation of levodopa for Parkinson's disease, raised $45 million by offering 4.5 million shares at $10, below the range of $13 to $16. NeuroDerm plans to list on the NASDAQ under the symbol NDRM. Jefferies and Cowen & Company acted as lead managers on the deal. The company's lead candidates are in Phase 2 trials for moderate and...read more